Literature DB >> 34292559

Impact of Socioeconomic Factors and Gender on Refill Adherence and Persistence to Lipid-Lowering Therapy in Type 1 Diabetes.

Christel Hero1,2, Sofia Axia Karlsson3, Stefan Franzén4,5, Ann-Marie Svensson6,4, Mervete Miftaraj4, Soffia Gudbjörnsdottír6,4, Karolina Andersson-Sundell3,7, Björn Eliasson6,8, Katarina Eeg-Olofsson6,8.   

Abstract

INTRODUCTION: Lipid-lowering therapy (LLT) reduces the risk of cardiovascular disease (CVD) in patients with type 1 diabetes (T1D). However, socioeconomic factors and gender may have an impact on the adherence to and non-persistence with LLT.
METHODS: This was a nationwide register-based cohort study that included 6192 individuals with T1D aged ≥ 18 years who were registered in the Swedish National Diabetes Register and had initiated novel use of LLT. Information on socioeconomic parameters (source: Statistics Sweden) and comorbidity (source: National Patient Register) was collected. The individuals were followed for 36 months, and adherence to LLT was analyzed according to age, socioeconomics and gender. The medication possession ratio (MPR; categorized into ≤ 80% and > 80%) and non-persistence (discontinuation) with medication was calculated after 18 and 36 months.
RESULTS: Individuals older than 53 years were more adherent to LLT (MPR > 80%) than those younger than 36 years (odds ratio [(OR] 1.30, p < 0.0001) at 36 months. Women were more adherent and less prone to discontinue LLT at 18 months (OR 1.05, p = 0.0005 and OR 0.95, p = 0.0004, respectively), but not at 36 months. Divorced individuals were less adherent than married ones (OR 0.93, p = 0.0005) and discontinued LLT more often than the latter (OR 1.06, p = 0.003). Education had no impact on adherence, but individuals with higher incomes discontinued LLT less frequently than those with lower incomes. Individuals with a country of origin other than Sweden discontinued LLT more often.
CONCLUSION: Lower adherence to LLT in individuals with T1D was associated with male gender, younger age, marital status and country of birth. These factors should be considered when evaluating adherence to LLT in clinical practice, with the aim to help patients achieve full cardioprotective treatment.
© 2021. The Author(s).

Entities:  

Keywords:  Adherence; Lipid-lowering therapy; Persistence; Socioeconomic status; Socioeconomy; Statin therapy; Type 1 diabetes

Year:  2021        PMID: 34292559     DOI: 10.1007/s13300-021-01115-w

Source DB:  PubMed          Journal:  Diabetes Ther        ISSN: 1869-6961            Impact factor:   2.945


  38 in total

1.  Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.

Authors:  Aidin Rawshani; Araz Rawshani; Stefan Franzén; Björn Eliasson; Ann-Marie Svensson; Mervete Miftaraj; Darren K McGuire; Naveed Sattar; Annika Rosengren; Soffia Gudbjörnsdottir
Journal:  N Engl J Med       Date:  2017-04-13       Impact factor: 91.245

2.  Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.

Authors:  Araz Rawshani; Naveed Sattar; Stefan Franzén; Aidin Rawshani; Andrew T Hattersley; Ann-Marie Svensson; Björn Eliasson; Soffia Gudbjörnsdottir
Journal:  Lancet       Date:  2018-08-09       Impact factor: 79.321

3.  Association Between Use of Lipid-Lowering Therapy and Cardiovascular Diseases and Death in Individuals With Type 1 Diabetes.

Authors:  Christel Hero; Araz Rawshani; Ann-Marie Svensson; Stefan Franzén; Björn Eliasson; Katarina Eeg-Olofsson; Soffia Gudbjörnsdottir
Journal:  Diabetes Care       Date:  2016-04-18       Impact factor: 19.112

4.  Life expectancy of type 1 diabetic patients during 1997-2010: a national Australian registry-based cohort study.

Authors:  Lili Huo; Jessica L Harding; Anna Peeters; Jonathan E Shaw; Dianna J Magliano
Journal:  Diabetologia       Date:  2016-01-21       Impact factor: 10.122

5.  Impact of better adherence to statin agents in the primary prevention of coronary artery disease.

Authors:  Sylvie Perreault; Alice Dragomir; Lucie Blais; Anick Bérard; Lyne Lalonde; Michel White; Danielle Pilon
Journal:  Eur J Clin Pharmacol       Date:  2009-06-16       Impact factor: 2.953

6.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Authors:  François Mach; Colin Baigent; Alberico L Catapano; Konstantinos C Koskinas; Manuela Casula; Lina Badimon; M John Chapman; Guy G De Backer; Victoria Delgado; Brian A Ference; Ian M Graham; Alison Halliday; Ulf Landmesser; Borislava Mihaylova; Terje R Pedersen; Gabriele Riccardi; Dimitrios J Richter; Marc S Sabatine; Marja-Riitta Taskinen; Lale Tokgozoglu; Olov Wiklund
Journal:  Eur Heart J       Date:  2020-01-01       Impact factor: 29.983

Review 7.  Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences.

Authors:  Rajiv Chowdhury; Hassan Khan; Emma Heydon; Amir Shroufi; Saman Fahimi; Carmel Moore; Bruno Stricker; Shanthi Mendis; Albert Hofman; Jonathan Mant; Oscar H Franco
Journal:  Eur Heart J       Date:  2013-08-01       Impact factor: 29.983

8.  Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database.

Authors:  Yana Vinogradova; Carol Coupland; Peter Brindle; Julia Hippisley-Cox
Journal:  BMJ       Date:  2016-06-28

9.  Refill adherence and persistence to lipid-lowering medicines in patients with type 2 diabetes: A nation-wide register-based study.

Authors:  Sofia Axia Karlsson; Christel Hero; Björn Eliasson; Stefan Franzén; Ann-Marie Svensson; Mervete Miftaraj; Soffia Gudbjörnsdottir; Katarina Eeg-Olofsson; Karolina Andersson Sundell
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-08-11       Impact factor: 2.890

10.  Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.

Authors:  P M Kearney; L Blackwell; R Collins; A Keech; J Simes; R Peto; J Armitage; C Baigent
Journal:  Lancet       Date:  2008-01-12       Impact factor: 79.321

View more
  2 in total

1.  Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy.

Authors:  Luca Degli Esposti; Chiara Veronesi; Domenica Daniela Ancona; Margherita Andretta; Fausto Bartolini; Alberto Drei; Alessandro Lupi; Stefano Palcic; Davide Re; Francesca Vittoria Rizzi; Elisa Giacomini; Valentina Perrone
Journal:  Clinicoecon Outcomes Res       Date:  2022-03-10

2.  Comorbidities in Recent-Onset Adult Type 1 Diabetes: A Comparison of German Cohorts.

Authors:  Oana P Zaharia; Stefanie Lanzinger; Joachim Rosenbauer; Wolfram Karges; Karsten Müssig; Sebastian M Meyhöfer; Volker Burkart; Michael Hummel; Dirk Raddatz; Michael Roden; Julia Szendroedi; Reinhard W Holl
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-03       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.